Smith SK, Miloh T. Pediatric liver transplantation. Clin Liver Dis. 2022;26(3):521–35.

Article  PubMed  Google Scholar 

Miloh T, Barton A, Wheeler J, Pham Y, Hewitt W, Keegan T, et al. Immunosuppression in pediatric liver transplant recipients: unique aspects. Liver Transpl. 2017;23(2):244–56.

Article  PubMed  Google Scholar 

Farouk SS, Rein JL. The many faces of calcineurin inhibitor toxicity—what the FK? Adv Chronic Kidney Dis. 2020;27(1):56–66.

Article  PubMed  PubMed Central  Google Scholar 

Charlton M, Levitsky J, Aqel B, O’Grady J, Hemibach J, Rinella M, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 2018;102(5):727–43.

Article  PubMed  Google Scholar 

Dumortier J, Couchonnal E, Lacaille F, Rivet C, Debray D, Boillot O, et al. mTOR inhibitors in pediatric liver transplant recipients. Clin Res Hepatol Gastroenterol. 2019;43(4):403–9.

Article  CAS  PubMed  Google Scholar 

Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl. 2001;7(6):473–84.

Article  CAS  PubMed  Google Scholar 

Dunn C, Croom KF. Everolimus: a review of its use in renal and cardiac transplantation. Drugs. 2006;66:547–70.

Article  CAS  PubMed  Google Scholar 

Pape L, Ahlenstiel T. mTOR inhibitors in pediatric kidney transplantation. Pediatr Nephrol. 2014;29:1119–29.

Article  PubMed  Google Scholar 

Schachter AD, Benfield MR, Wyatt RJ, Grimm PC, Fennell RS, Herrin JT, et al. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. Pediatr Transplant. 2006;10(8):914–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J Transplant. 2014;2014:1–45.

Article  Google Scholar 

Nashan B. mTOR inhibition and clinical transplantation: liver. Transplantation. 2018;102(2S):S19–26.

Article  CAS  PubMed  Google Scholar 

Glover TE, Watson CJ, Gibbs P, Bradley JA, Ntzani EE, Kosmoliaptsis V. Conversion from calcineurin to mammalian target of rapamycin inhibitors in liver transplantation: a meta-analysis of randomized controlled trials. Transplantation. 2016;100(3):621–9.

Article  CAS  PubMed  Google Scholar 

Grigg SE, Sarri GL, Gow PJ, Yeomans ND. Systematic review with meta-analysis: sirolimus-or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2019;49(10):1260–73.

Article  CAS  PubMed  Google Scholar 

Wehming M, Krebs-Schmitt D, Briem-Richter A, Hegen B, Brinkert F, Fischer L, et al. Experience with the mTOR inhibitor everolimus in pediatric liver graft recipients. Children. 2023;10(2):367.

Article  PubMed  PubMed Central  Google Scholar 

Ganschow R, Ericzon BG, Dhawan A, Sharif K, Martzloff ED, Rauer B, et al. Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: results from a multicenter, prospective study. Pediatr Transplant. 2017;21(7): e13024.

Article  Google Scholar 

Basso MS, Subramaniam P, Tredger M, Verma A, Heaton N, Rela M, et al. Sirolimus as renal and immunological rescue agent in pediatric liver transplant recipients. Pediatr Transplant. 2011;15(7):722–7.

Article  CAS  PubMed  Google Scholar 

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Internal Med. 2009;151(4):W65–94.

Article  Google Scholar 

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.

Article  PubMed  PubMed Central  Google Scholar 

Sindhi R, Seward J, Mazariegos G, Soltys K, Seward L, Smith A, et al. Replacing calcineurin inhibitors with mTOR inhibitors in children. Pediatr Transplant. 2005;9(3):391–7.

Article  CAS  PubMed  Google Scholar 

Markiewicz M, Kalicinski P, Teisseyre J, Ismail H, Kaminski A, Teisseyre M, editors. Rapamycin in children after liver transplantation. Transplantation proceedings. Elsevier; 2003.

Casas-Melley AT, Falkenstein KP, Flynn LM, Ziegler VL, Dunn SP. Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus. Pediatr Transplant. 2004;8(4):362–6.

Article  CAS  PubMed  Google Scholar 

Hendrickson RJ, Sujka J, Fischer R, Manalang M, Daniel J, Andrews WS. Indications and efficacy of conversion from tacrolimus-to sirolimus-based immunosuppression in pediatric patients who underwent liver transplantation for unresectable hepatoblastoma. Pediatr Transplant. 2019;23(3): e13369.

Article  PubMed  Google Scholar 

Ueno T, Kodama T, Noguchi Y, Deguchi K, Nomura M, Saka R, et al., editors. Safety and efficacy of everolimus rescue treatment after pediatric living donor liver transplantation. Transplantation Proceedings. Elsevier; 2020.

Nielsen D, Briem-Richter A, Sornsakrin M, Fischer L, Nashan B, Ganschow R. The use of everolimus in pediatric liver transplant recipients: first experience in a single center. Pediatr Transplant. 2011;15(5):510–4.

Article  CAS  PubMed  Google Scholar 

Shinke H, Hashi S, Kinoshita R, Taniguchi R, Sugimoto M, Matsubara K, et al. Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. Biol Pharm Bull. 2013;36(7):1221–5.

Article  CAS  PubMed  Google Scholar 

Hwang S, Namgoong J-M, Oh SH, Kim KM, Ahn C-S, Kwon H, et al. Effect of everolimus rescue therapy for acute cellular rejection following pediatric living donor liver transplantation: report of one case. Ann Hepatobiliary Pancreat Surg. 2020;24(2):216–20.

Article  PubMed  PubMed Central  Google Scholar 

Nishioka S, Ishimura T, Endo T, Yokoyama N, Ogawa S, Fujisawa M. Suppression of allograft fibrosis by regulation of mammalian target of rapamycin-related protein expression in kidney-transplanted recipients treated with everolimus and reduced tacrolimus. Ann Transplant. 2021;26:e926476–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiménez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant. 2004;8(3):243–8.

Article  PubMed  Google Scholar 

Gibelli N, Tannuri U, Pinho-Apezzato M, Tannuri A, Maksoud-Filho J, Andrade W, et al., editors. Sirolimus in pediatric liver transplantation: a single-center experience. Transplantation proceedings. Elsevier; 2009.

Al-Akash SI, Al Makadma AS, Al Omari MG. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy. Pediatr Transplant. 2005;9(2):249–53.

Article  PubMed  Google Scholar 

Wehming M, Briem-Richter A, Ganschow R, Brinkert F, Winkler B, Fischer L, et al. Malignancies and pediatric liver transplantation: promising management with the mTOR-inhibitor everolimus. OBM Transplant. 2021;5(1):1–15.

Article  Google Scholar 

Leiskau C, Junge N, Mutschler FE, Laue T, Ohlendorf J, Richter N, et al. Long-term outcome following liver transplantation for primary hepatic tumors—a single centre observational study over 40 years. Children. 2023;10(2):202.

Article  PubMed  PubMed Central  Google Scholar 

Boster JM, Superina R, Mazariegos GV, Tiao GM, Roach JP, Lovell MA, et al. Predictors of survival following liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma: experience from the Society of Pediatric Liver Transplantation (SPLIT). Am J Transplant. 2022;22(5):1396–408.

Article  PubMed  Google Scholar 

Yuksekkaya HA, Arikan C, Yazici A, Baran M, Aydogdu S, Kilic M. Successful treatment of a child having generalized Kaposi’s sarcoma after living donor liver transplantation with conversion to sirolimus. Pediatr Transplant. 2009;13(3):375–8.

Article  PubMed